[Effectiveness of recombinant activated factor VIIA (NovoSeven) in case of severe obstetric complication with coagulopathy].
The aim of report is to present the possibilities of applying NovoSeven in serious coagulopathy in course of various obstetrical complications. At present it is utilised in acquired coagulopathy, bleedings, traumatic cases and extensive surgical operations especially associated with DIC. We report two cases of severe complications during delivery. Both patients had a massive bleeding, severe disorders of haemostasis, which on effect were leading to DIC. In therapy a large quantity of blood products were applied. Conventional treatment with anticoagulant did not give any results. Administration of NovoSeven gave at last radical turn in course of treatment and the improvement in patient's state. In obstetrical practice NovoSeven is recommendable supplement of conventional treatment in severe coagulopathy.
Bielanów
Tomasz
T
Szpitala Specjalistycznego im. A Falkiewicza we Wrocławiu.
Sidor
Mariusz
M
Maciejewski
Michał
M
Skrzypek
Witold
W
D000328:Adult; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006473:Postpartum Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D011994:Recombinant Proteins; D015942:Factor VIIa